Continuous administration of poloxamer 188 reduces overload-induced muscular atrophy in dysferlin-deficient SJL mice

Neuroscience Research

Volumn 72, Issue 2, 2012, Pages 181-186

  Suzuki, Naoki ^a   Akiyama, Tetsuya ^a   Takahashi, Toshiaki ^b   Komuro, Hazuki ^a   Warita, Hitoshi ^a   Tateyama, Maki ^a   Itoyama, Yasuto ^c   Aoki, Masashi ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b National Hospital Organization Sendai Nishitaga Hospital   (Japan)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

Atrogin 1; Dysferlinopathy; Muscular dystrophy; Osmotic pump; P38; Poloxamer 188 (P188)

Indexed keywords

ATROGIN 1; DYSFERLIN; POLOXAMER; SYNAPTOPHYSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DYSFERLINOPATHY; ENDURANCE TRAINING; ENZYME PHOSPHORYLATION; FEMALE; GASTROCNEMIUS MUSCLE; MOTOR PERFORMANCE; MOUSE; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE MASS; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SOLEUS MUSCLE; TIBIALIS ANTERIOR MUSCLE; TREATMENT DURATION;

ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; EXCIPIENTS; FEMALE; MEMBRANE PROTEINS; MICE; MICE, MUTANT STRAINS; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; MUSCULAR ATROPHY; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; POLOXAMER; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKP CULLIN F-BOX PROTEIN LIGASES;

EID: 84855344491     PISSN: 01680102     EISSN: 18728111     Source Type: Journal    
DOI: 10.1016/j.neures.2011.10.005     Document Type: Article

References (30)

1. Adams-Graves P., Kedar A., Koshy M., Steinberg M., Veith R., Ward D., Crawford R., Edwards S., Bustrack J., Emanuele M. RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study. Blood 1997, 90:2041-2046.
2. Aoki M., Liu J., Richard I., Bashir R., Britton S., Keers S.M., Oeltjen J., Brown H.E., Marchand S., Bourg N., Beley C., McKenna-Yasek D., Arahata K., Bohlega S., Cupler E., Illa I., Majneh I., Barohn R.J., Urtizberea J.A., Fardeau M., Amato A., Angelini C., Bushby K., Beckmann J.S., Brown R.H. Genomic organization of the dysferlin gene and novel mutations in Miyoshi myopathy. Neurology 2001, 57:271-278.
3. Bansal D., Miyake K., Vogel S.S., Groh S., Chen C.C., Williamson R., McNeil P.L., Campbell K.P. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 2003, 423:168-172.
4. Bashir R., Britton S., Strachan T., Keers S., Vafiadaki E., Lako M., Richard I., Marchand S., Bourg N., Argov Z., Sadeh M., Mahjneh I., Marconi G., Passos-Bueno M.R., Moreira Ede S., Zatz M., Beckmann J.S., Bushby K. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat. Genet. 1998, 20:37-42.
5. Bittner R.E., Anderson L.V., Burkhardt E., Bashir R., Vafiadaki E., Ivanova S., Raffelsberger T., Maerk I., Hoger H., Jung M., Karbasiyan M., Storch M., Lassmann H., Moss J.A., Davison K., Harrison R., Bushby K.M., Reis A. Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. Nat. Genet. 1999, 23:141-142.
6. Borgens R.B., Bohnert D., Duerstock B., Spomar D., Lee R.C. Subcutaneous tri-block copolymer produces recovery from spinal cord injury. J. Neurosci. Res. 2004, 76:141-154.
7. Illa I., Serrano-Munuera C., Gallardo E., Lasa A., Rojas-Garcia R., Palmer J., Gallano P., Baiget M., Matsuda C., Brown R.H. Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. Ann. Neurol. 2001, 49:130-134.
8. Illarioshkin S.N., Ivanova-Smolenskaya I.A., Greenberg C.R., Nylen E., Sukhorukov V.S., Poleshchuk V.V., Markova E.D., Wrogemann K. Identical dysferlin mutation in limb-girdle muscular dystrophy type 2B and distal myopathy. Neurology 2000, 55:1931-1933.
9. Keren A., Tamir Y., Bengal E. The p38 MAPK signaling pathway: a major regulator of skeletal muscle development. Mol. Cell. Endocrinol. 2006, 252:224-230.
10. Klinge L., Aboumousa A., Eagle M., Hudson J., Sarkozy A., Vita G., Charlton R., Roberts M., Straub V., Barresi R., Lochmuller H., Bushby K. New aspects on patients affected by dysferlin deficient muscular dystrophy. J. Neurol. Neurosurg. Psychiatry 2010, 81:946-953.
11. Lee R.C., River L.P., Pan F.S., Ji L., Wollmann R.L. Surfactant-induced sealing of electropermeabilized skeletal muscle membranes in vivo. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:4524-4528.
12. Liu J., Aoki M., Illa I., Wu C., Fardeau M., Angelini C., Serrano C., Urtizberea J.A., Hentati F., Hamida M.B., Bohlega S., Culper E.J., Amato A.A., Bossie K., Oeltjen J., Bejaoui K., McKenna-Yasek D., Hosler B.A., Schurr E., Arahata K., de Jong P.J., Brown R.H. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat. Genet. 1998, 20:31-36.
13. Maskarinec S.A., Wu G., Lee K.Y. Membrane sealing by polymers. Ann. N.Y. Acad. Sci. 2005, 1066:310-320.
14. McClung J.M., Judge A.R., Powers S.K., Yan Z. p38 MAPK links oxidative stress to autophagy-related gene expression in cachectic muscle wasting. Am. J. Physiol. Cell Physiol. 2010, 298:C542-C549.
15. Merchant F.A., Holmes W.H., Capelli-Schellpfeffer M., Lee R.C., Toner M. Poloxamer 188 enhances functional recovery of lethally heat-shocked fibroblasts. J. Surg. Res. 1998, 74:131-140.
16. Murphy A.D., McCormack M.C., Bichara D.A., Nguyen J.T., Randolph M.A., Watkins M.T., Lee R.C., Austen W.G. Poloxamer 188 protects against ischemia-reperfusion injury in a murine hind-limb model. Plast. Reconstr. Surg. 2010, 125:1651-1660.
17. Ng R., Metzger J.M., Claflin D.R., Faulkner J.A. Poloxamer 188 reduces the contraction-induced force decline in lumbrical muscles from mdx mice. Am. J. Physiol. Cell Physiol. 2008, 295:C146-C150.
18. Paradas C., Llauger J., Diaz-Manera J., Rojas-Garcia R., De Luna N., Iturriaga C., Marquez C., Uson M., Hankiewicz K., Gallardo E., Illa I. Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies. Neurology 2010, 75:316-323.
19. Quinlan J.G., Wong B.L., Niemeier R.T., McCullough A.S., Levin L., Emanuele M. Poloxamer 188 failed to prevent exercise-induced membrane breakdown in mdx skeletal muscle fibers. Neuromuscul. Disord. 2006, 16:855-864.
20. Rayavarapu S., Van der Meulen J.H., Gordish-Dressman H., Hoffman E.P., Nagaraju K., Knoblach S.M. Characterization of dysferlin deficient SJL/J mice to assess preclinical drug efficacy: fasudil exacerbates muscle disease phenotype. PLoS One 2010, 5:e12981.
21. Rosales X.Q., Gastier-Foster J.M., Lewis S., Vinod M., Thrush D.L., Astbury C., Pyatt R., Reshmi S., Sahenk Z., Mendell J.R. Novel diagnostic features of dysferlinopathies. Muscle Nerve 2010, 42:14-21.
22. Saito H., Suzuki N., Ishiguro H., Hirota K., Itoyama Y., Takahashi T., Aoki M. Distal anterior compartment myopathy with early ankle contractures. Muscle Nerve 2007, 36:525-527.
23. Serbest G., Horwitz J., Jost M., Barbee K. Mechanisms of cell death and neuroprotection by poloxamer 188 after mechanical trauma. FASEB J. 2006, 20:308-310.
24. Suzuki N., Aoki M., Hinuma Y., Takahashi T., Onodera Y., Ishigaki A., Kato M., Warita H., Tateyama M., Itoyama Y. Expression profiling with progression of dystrophic change in dysferlin-deficient mice (SJL). Neurosci. Res. 2005, 52:47-60.
25. Suzuki N., Motohashi N., Uezumi A., Fukada S., Yoshimura T., Itoyama Y., Aoki M., Miyagoe-Suzuki Y., Takeda S. NO production results in suspension-induced muscle atrophy through dislocation of neuronal NOS. J. Clin. Invest. 2007, 117:2468-2476.
26. Takahashi T., Aoki M., Tateyama M., Kondo E., Mizuno T., Onodera Y., Takano R., Kawai H., Kamakura K., Mochizuki H., Shizuka-Ikeda M., Nakagawa M., Yoshida Y., Akanuma J., Hoshino K., Saito H., Nishizawa M., Kato S., Saito K., Miyachi T., Yamashita H., Kawai M., Matsumura T., Kuzuhara S., Ibi T., Sahashi K., Nakai H., Kohnosu T., Nonaka I., Arahata K., Brown R.H., Itoyama Y. Dysferlin mutations in Japanese Miyoshi myopathy: relationship to phenotype. Neurology 2003, 60:1799-1804.
27. Townsend D., Turner I., Yasuda S., Martindale J., Davis J., Shillingford M., Kornegay J.N., Metzger J.M. Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs. J. Clin. Invest. 2010, 120:1140-1150.
28. Wu G., Majewski J., Ege C., Kjaer K., Weygand M.J., Lee K.Y. Interaction between lipid monolayers and poloxamer 188: an X-ray reflectivity and diffraction study. Biophys. J. 2005, 89:3159-3173.
29. Yamamoto Y., Hoshino Y., Ito T., Nariai T., Mohri T., Obana M., Hayata N., Uozumi Y., Maeda M., Fujio Y., Azuma J. Atrogin-1 ubiquitin ligase is upregulated by doxorubicin via p38-MAP kinase in cardiac myocytes. Cardiovasc. Res. 2008, 79:89-96.
30. Yasuda S., Townsend D., Michele D.E., Favre E.G., Day S.M., Metzger J.M. Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 2005, 436:1025-1029.